Regaine

Women’s REGAINE Regular Strength Minoxidil Topical Solution is clinically proven to help regrow hair in some women. The hair loss treatment reactivates hair follicles to stimulate regrowth.

Regaine is for the treatment of hereditary hair loss in women.
- Apply twice a day
- Easy to use at home as part of your daily routine
- If your hair loss is greater than the level shown on the side of the package, Regaine is less likely to work. (See insert for more information).
- It takes time to regrow hair. You may need to use Regaine for at least 4 months before you see results.
- Continual use is necessary to improve and at least maintain your hair growth.

A hair regrowth treatment clinically proven to help stimulate hair growth in some people with hereditary hair loss.
Regaine is a hair growth product for women who have a general thinning hair at the top of the head (vertex).

How does Women’s REGAINE Solution work?
- Contains 2% minoxidil which is clinically proven to treat hereditary hair loss
- Reactivates hair follicles to stimulate regrowth
- Increases and prolongs the hair growth phase
- Allows for normal, healthy hair to develop over time

This pack contains a 3 month supply.

Regrow your hair with Regaine Women's Once A Day Extra Strength Foam. This minoxidil foam reactivates hair follicles to stimulate regrowth. Make this hair loss treatment for women a part of your everyday routine for results you may begin to see in as little as 12 weeks*.

Is this suitable for your type of hair loss?
Women's Regaine is for women who have general thinning of hair at the top of the scalp (vertex).

Women’s REGAINE Foam is:
- A once-a-day hair regrowth treatment
- Easy to use
- Fast drying. This hair loss product doesn’t interfere with your hair care routine.

How does Women’s REGAINE Foam work?
- Reactivates hair follicles to stimulate regrowth
- Increases and prolongs the hair growth phase
- Helps grow lhicker hair follicles over time
5% minoxidil topical foam w/w

This pack contains a 2 month supply (2 x 60g).

*Blume-Peytavi et al. J Drugs Dermatol. 2016;15(7):883-889